10-Q: Tyra Biosciences Reports Q2 2026 Results, Expenses Rise

Tyra Biosciences, Inc. announced its Q2 2026 financial results, highlighting increased research and development spending and a widening net loss, while also noting progress in its clinical pipeline and a strong cash position extending into late 2028.

Summary

• Tyra Biosciences reported a net loss of $45.6 million for the three months ended June 30, 2026, compared to a loss of $28.1 million in the same period last year.
• For the six months ended June 30, 2026, the net loss was $84.9 million, up from $56.2 million in the prior year.
• Total operating expenses increased to $49.0 million for the quarter and $91.0 million for the six months, driven by higher research and development (R&D) and general and administrative (G&A) costs.
• R&D expenses rose to $39.2 million for the quarter and $72.7 million for the six months, largely due to increased external costs for dabogratinib development and higher personnel expenses.
• G&A expenses increased to $9.8 million for the quarter and $18.3 million for the six months, attributed to higher compensation and stock-based compensation costs.
• As of June 30, 2026, the company had $353.9 million in cash, cash equivalents, and marketable securities.
• Management expects current cash resources to fund operations into the second half of 2028.
• The company is advancing its dabogratinib program in three Phase 2 trials for urothelial cancers and achondroplasia, with initial results expected in 2027 for LG-UTUC and ACH trials, and September 2026 for the IR NMIBC trial.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to significant increases in operating expenses and net losses, despite a substantial cash position and ongoing development progress.

Positives

• The company maintains a strong liquidity position with $353.9 million in cash, cash equivalents, and marketable securities as of June 30, 2026.
• Management projects that current cash reserves will be sufficient to fund operations into the second half of 2028.
• Progress is being made in clinical development, with ongoing Phase 2 trials for dabogratinib in urothelial cancers (LG-UTUC and IR NMIBC) and achondroplasia (ACH).
• Initial results from the SURF302 (IR NMIBC) trial are expected in September 2026.
• The company has an at-the-market (ATM) offering program, with an amendment to increase the potential offering to $250.0 million.
• The company's proprietary SNP platform enables rapid and precise drug design.

Negatives

• Net loss for the three months ended June 30, 2026, was $45.6 million, a significant increase from $28.1 million in the prior year.
• Net loss for the six months ended June 30, 2026, was $84.9 million, up from $56.2 million in the prior year.
• Total operating expenses increased by $17.6 million to $49.0 million for the quarter and by $27.7 million to $91.0 million for the six months.
• Research and development expenses increased by $14.9 million to $39.2 million for the quarter and by $23.4 million to $72.7 million for the six months.
• General and administrative expenses increased by $2.7 million to $9.8 million for the quarter and by $4.3 million to $18.3 million for the six months.
• The company has not generated any revenue to date and expects to continue incurring significant expenses and operating losses.
• The weighted-average net loss per share increased to $0.69 for the quarter and $1.33 for the six months, compared to $0.47 and $0.95, respectively, in the prior year.

Risks

• The company has incurred significant operating losses since inception and expects to continue to incur significant expenses and increasing operating losses for the foreseeable future.
• The company may not be able to raise additional funds or enter into other capital arrangements when needed or on favorable terms, which could force it to delay, limit, reduce, or terminate its research and development programs or future commercialization efforts.
• The development of product candidates is costly and time-consuming, and there is no guarantee of success in achieving regulatory approval.
• Future regulatory factors beyond the company's control may impact clinical development programs.
• The company will lose its emerging growth company status at the end of 2026, requiring compliance with additional disclosure requirements.
• The company will cease to be a smaller reporting company starting in Q1 2027, also leading to increased disclosure and compliance requirements.

Future Outlook

Based on the current operating plan, the company believes its cash, cash equivalents, and marketable securities as of June 30, 2026, will be sufficient to fund its operating expenses and capital expenditures into the second half of 2028. The company expects to continue incurring significant expenses and increasing operating losses as it advances its product candidates through clinical trials and development.

Management Comments

• We are currently advancing oral dabogratinib in three Phase 2 trials for three outsized market indications: SURF303, evaluating the treatment of low-grade upper tract urothelial carcinoma (LG-UTUC); SURF302, evaluating the treatment of intermediate risk non-muscle invasive bladder cancer (IR NMIBC); and BEACH301, evaluating the treatment of achondroplasia (ACH) in children.
• If we are successful with these Phase 2 studies, we expect to advance oral dabogratinib toward three potential registrational trials in LG-UTUC, IR NMIBC and ACH. We are calling this approach our dabogratinib 3x3 strategy.
• Based on our current operating plan, we believe that our cash, cash equivalents and marketable securities as of June 30, 2026 will be sufficient to fund our operating expenses and capital expenditures into the second half of 2028.
• We have never generated any revenue and do not expect to generate any revenue from product sales unless and until we successfully complete the development of and obtain regulatory approval for our product candidates, which will not be for several years, if ever.

Industry Context

StockSavvy.ai notes that Tyra Biosciences operates in the highly competitive and capital-intensive clinical-stage biotechnology sector. The company's focus on FGFR biology aligns with industry trends of developing targeted therapies for specific genetic alterations in oncology and rare diseases. However, the significant increase in R&D spending and net losses is typical for companies at this stage, underscoring the high risk and long development timelines inherent in the industry.

Comparison to Industry Standards

• Companies in the clinical-stage biotechnology sector, particularly those focused on oncology and rare diseases, typically incur substantial R&D expenses without generating revenue for several years, similar to Tyra Biosciences.
• The net loss of $45.6 million for the quarter and $84.9 million for the six months, while substantial, is not unusual for companies advancing multiple drug candidates through Phase 2 trials.
• The cash runway extending into the second half of 2028 is a positive indicator, suggesting sufficient funding for near-to-medium term development milestones, which is a key metric investors evaluate in this sector.
• The company's strategy of pursuing multiple indications for its lead candidate, dabogratinib (the 'dabogratinib 3x3 strategy'), is a common approach to maximize the potential of a promising drug candidate, though it also increases development costs and complexity.

Legal Proceedings

• The company was not subject to any material legal proceedings as of June 30, 2026, and no material legal proceedings are currently pending or threatened.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• The increasing net losses and expenses could impact investor confidence and potentially the stock price.
• Successful development of product candidates could lead to significant value creation for shareholders.
• Employees' stock-based compensation is a significant expense, reflecting investment in human capital.

Next Steps

• Report initial results from the SURF302 (IR NMIBC) trial in September 2026.
• Report initial results from the BEACH301 (ACH) safety sentinel cohort, including 6-month annualized height velocity and safety data from all five dose levels, at the end of Q1 2027.
• Report initial results from the SURF303 (LG-UTUC) trial in 2027.
• Advance oral dabogratinib toward potential registrational trials in LG-UTUC, IR NMIBC, and ACH if Phase 2 studies are successful.
• Continue research and development activities for other product candidates (TYRA-430, TYRA-200) and pipeline expansion.
• Continue to fund operations with existing cash reserves, expected to last into the second half of 2028.
• Potentially utilize the amended at-the-market offering program to raise up to $250.0 million.

Key Dates

Recommendation

While Tyra Biosciences shows promising pipeline development and a strong cash position, the significant increase in operating expenses and net losses, coupled with the lack of revenue, warrants a cautious approach. The company's ability to execute its clinical trials and secure future funding are key factors. A 'hold' recommendation reflects the balance between potential upside from pipeline progress and the inherent risks of clinical-stage biotech.

Keywords

biotechnology, clinical-stage, FGFR, precision medicine, oncology, urothelial cancer, achondroplasia, drug development